A lot of pharma companies declare that they no longer want to be purely developers of drugs, and thus they progressively transition to become healthcare solution providers, trying to seek broader solutions to answer the patient needs, and changing the way they look at assets: What does it mean for the industry in terms of orientation of their scouting efforts, particularly for early-stage assets?
This session aims to understand pharma’s viewpoint, the consequences for the orientation of deals, the way it is going to influence the relationships with academia and biotech start-ups. How does this strategic intention modify the type and the nature of deals that pharma have with start-ups & academic institutions? How is it affecting early-stage licensing deals?

Gerald Law - Innovation DB (UK Innovation Forum)
James Eshelby - Pfizer
Phil L’Huillier - Merck Sharp & Dohme
Tomas Landh - Novo Nordisk
Joachim Vogt - AbbVie

Continue your tour